GCP
COYA icon

GSA Capital Partners’s Coya Therapeutics COYA Stock Holding History

GSA Capital Partners’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,701
Closed -$120K – 1796
2025
Q4 		$120K Buy
+20,701
New +$126K 0.01% 1509

Other funds holding COYA

DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

GSA Capital Partners's COYA Position: Q1 2026 in Review

GSA Capital Partners sold out of Coya Therapeutics (COYA) in Q1 2026, closing a stake of 20,701 shares — an estimated $120K sold.

GSA Capital Partners first reported a position in COYA in Q4 2025 and held it in 1 quarter. The position peaked at $120K in Q4 2025. 56 funds tracked by Wall St. Rank hold COYA as of Q1 2026.

  • GSA Capital Partners reported no remaining Coya Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 20,701 Coya Therapeutics shares in Q1 2026, an estimated $120K.
  • GSA Capital Partners first reported a position in Coya Therapeutics in Q4 2025 and held it in 1 quarter.
  • GSA Capital Partners's Coya Therapeutics position peaked at $120K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Coya Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.